{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:52:15Z","timestamp":1767772335894,"version":"3.30.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2679,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>It has been reported that salicylates (sodium salicylate and aspirin) inhibit the replication of flaviviruses, such as Japanese encephalitis virus and dengue virus. Therefore, we considered it important to test whether acetylsalicylic acid (ASA) had anti\u2013hepatitis C virus (HCV) activity. To this end, we examined the effects of ASA on viral replication and protein expression, using an HCV subgenomic replicon cell culture system. We incubated Huh7 replicon cells with 2-8 mM ASA for different times and measured HCV-RNA and protein levels by northern blot, real-time polymerase chain reaction, and western analysis, respectively. We found that ASA had a suppressive effect on HCV-RNA and protein levels (nearly 58%). ASA-dependent inhibition of HCV expression was not mediated by the 5\u2032-internal ribosome entry site or 3\u2032-untranslated regions, as determined by transfection assays using bicistronic constructs containing these regulatory regions. However, we found that HCV-induced cyclooxygenase 2 (COX-2) messenger RNA and protein levels and activity and these effects were down-regulated by ASA, possibly by a nuclear factor kappa B\u2013independent mechanism. We also observed that the ASA-dependent inhibition of viral replication was due in part to inhibition of COX-2 and activation of p38 and mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 (MEK1\/2) mitogen-activated protein kinases (MAPKs). Inhibition of these kinases by SB203580 and U0126, respectively, and by short interfering RNA silencing of p38 and MEK1 MAPK prevented the antiviral effect of ASA. Taken together, our findings suggest that the anti-HCV effect of ASA in the Huh7 replicon cells is due to its inhibitory effect on COX-2 expression, which is mediated in part by the activation of MEK1\/2\/p38 MAPK.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>These findings suggest the possibility that ASA could be an excellent adjuvant in the treatment of chronic HCV infection.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22215","type":"journal-article","created":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T15:18:21Z","timestamp":1202397501000},"page":"1462-1472","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":69,"title":["Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways"],"prefix":"10.1097","volume":"47","author":[{"given":"Karina","family":"Trujillo-Murillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rosa","family":"Rinc\u00f3n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herminia","family":"Mart\u00ednez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bosques-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ramos-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo A.","family":"Barrera-Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Rojkind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Rivas-Estilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20241201","first-page":"35","article-title":"Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.","volume":"6","year":"1999","journal-title":"J Viral Hepat"},{"key":"R2-6-20241201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection.","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-6-20241201","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R4-6-20241201","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C.","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"R5-6-20241201","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.antiviral.2006.06.006","article-title":"Selective inhibitors of hepatitis C virus replication.","volume":"71","author":"Neyts","year":"2006","journal-title":"Antiviral Res"},{"key":"R6-6-20241201","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"R7-6-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(01)00164-4","article-title":"Novel cell culture systems for the HCV.","volume":"52","author":"Bartenschlager","year":"2001","journal-title":"Antiviral Res"},{"key":"R8-6-20241201","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.1128\/JVI.75.17.7828-7839.2001","article-title":"Salicylates inhibit flavivirus replication independently of blocking NFkappaB activation.","volume":"75","author":"Liao","year":"2001","journal-title":"J Virol"},{"key":"R9-6-20241201","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid blocks influenza virus propagation via its NFkappaBinhibiting activity.","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol"},{"key":"R10-6-20241201","doi-asserted-by":"crossref","first-page":"11202","DOI":"10.1073\/pnas.91.23.11202","article-title":"Mechanism of selective inhibition of the inducible isoform of prostaglandin GH synthase.","volume":"91","author":"Copeland","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-6-20241201","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molbrainres.2003.09.006","article-title":"COX3: a splice variant of cyclooxygenase1 in mouse neural tissue and cells.","volume":"119","author":"Shaftel","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"R12-6-20241201","doi-asserted-by":"crossref","first-page":"9725","DOI":"10.1128\/JVI.79.15.9725-9734.2005","article-title":"Hepatitis C virus stimulates the expression of cyclooxygenase2 via oxidative stress: role of PGE2 in RNA replication.","volume":"79","author":"Waris","year":"2005","journal-title":"J Virol"},{"key":"R13-6-20241201","doi-asserted-by":"crossref","first-page":"23627","DOI":"10.1074\/jbc.M001381200","article-title":"An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase2 gene in human T lymphocytes.","volume":"275","author":"Iniguez","year":"2000","journal-title":"J Biol Chem"},{"key":"R14-6-20241201","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1128\/JVI.76.21.10637-10653.2002","article-title":"PKRdependent mechanisms of gene expression from a subgenomic hepatitis C virus clone.","volume":"76","author":"RivasEstilla","year":"2002","journal-title":"J Virol"},{"key":"R15-6-20241201","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1073\/pnas.83.21.8122","article-title":"Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7RNA polymerase.","volume":"83","author":"Fuerst","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-6-20241201","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Singlestep method of RNA isolation by acid guanidinium thiocyanatephenolchloroform extraction.","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"R17-6-20241201","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1074\/jbc.M412687200","article-title":"Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of HCV.","volume":"280","author":"Fillebeen","year":"2005","journal-title":"J Biol Chem"},{"key":"R18-6-20241201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2893.1999.00161.x","article-title":"Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C.","volume":"6","author":"Hyman","year":"1999","journal-title":"J Viral Hepat"},{"key":"R19-6-20241201","doi-asserted-by":"crossref","first-page":"12753","DOI":"10.1128\/JVI.77.23.12753-12763.2003","article-title":"COX2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.","volume":"77","author":"Symensma","year":"2003","journal-title":"J Virol"},{"key":"R20-6-20241201","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1073\/pnas.052713799","article-title":"Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication.","volume":"99","author":"Zhu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-6-20241201","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1074\/jbc.M010787200","article-title":"Overexpression of cyclooxygenase2 is sufficient to induce tumorigenesis in transgenic mice.","volume":"276","author":"Liu","year":"2001","journal-title":"J Biol Chem"},{"key":"R22-6-20241201","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/MCB.18.1.78","article-title":"Activation of p38 MAPK by sodium salicylate leads to inhibition of TNFinduced IkappaBalpha phosphorylation and degradation.","volume":"18","author":"Schwenger","year":"1998","journal-title":"Mol Cell Biol"},{"key":"R23-6-20241201","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1161\/01.RES.83.2.210","article-title":"Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase2 in coronary artery smooth muscle cells.","volume":"83","author":"Speir","year":"1998","journal-title":"Circ Res"},{"key":"R24-6-20241201","first-page":"397","article-title":"In vitro activity of ASA on replication of varicellazoster virus.","volume":"21","author":"Primache","year":"1998","journal-title":"New Microbiol"},{"key":"R25-6-20241201","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2006.00837.x","article-title":"Additive effect of ethanol and HCV subgenomic replicon expression on COX2 protein levels and activity.","volume":"14","author":"TrujilloMurillo","year":"2007","journal-title":"J Viral Hepat"},{"key":"R26-6-20241201","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/429301","article-title":"Effect of HCV core protein on cellular gene expression: specific inhibition of COX2.","volume":"191","author":"Jhaveri","year":"2005","journal-title":"J Infect Dis"},{"key":"R27-6-20241201","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1128\/JVI.79.12.7648-7657.2005","article-title":"HCV core protein suppresses NFkappaB activation and COX2 expression by direct interaction with IkappaB kinase beta.","volume":"79","author":"Joo","year":"2005","journal-title":"J Virol"},{"key":"R28-6-20241201","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1530-0277.1993.tb05234.x","article-title":"Nonsteroidal antiinflammatory drugs lower ethanolmediated liver increase in lipids and thiobarbituric acid reactive substances.","volume":"17","author":"Zentella de Pina","year":"1993","journal-title":"Alcohol Clin Exp Res"},{"key":"R29-6-20241201","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.1128\/JVI.78.18.9721-9730.2004","article-title":"Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step.","volume":"78","author":"Rossen","year":"2004","journal-title":"J Virol"},{"key":"R30-6-20241201","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1099\/0022-1317-83-8-1897","article-title":"Suppression of Japanese encephalitis virus infection by nonsteroidal antiinflammatory drugs.","volume":"83","author":"Chen","year":"2002","journal-title":"J Gen Virol"},{"key":"R31-6-20241201","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0891-5849(96)00131-1","article-title":"Oxidative stress during viral infection: a review.","volume":"21","author":"Schwarz","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"R32-6-20241201","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.1128\/JVI.74.18.8680-8691.2000","article-title":"Potential dengue virustriggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NFkappaB are sequentially involved.","volume":"74","author":"Jan","year":"2000","journal-title":"J Virol"},{"key":"R33-6-20241201","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.intimp.2006.01.009","article-title":"Inhibitor SP600125 reduces COX2 expression by attenuating mRNA in activated murine J774 macrophages.","volume":"6","author":"Nieminen","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R34-6-20241201","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/hep.510270332","article-title":"Tenoxicam, a nonsteroid antiinflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alphainterferon.","volume":"27","author":"Zarski","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R35-6-20241201","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2893.2003.00449.x","article-title":"Interferonalpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: a randomized controlled trial.","volume":"10","author":"Andreone","year":"2003","journal-title":"J Viral Hepat"},{"key":"R36-6-20241201","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/jlts.2003.50003","article-title":"Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic HCV infection.","volume":"9","author":"Firpi","year":"2003","journal-title":"Liver Transpl"},{"key":"R37-6-20241201","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1046\/j.1365-2036.1999.00613.x","article-title":"Interferon alfa2b alone or in combination with ketoprofen as treatment for interferonnaive chronic hepatitis C patients.","volume":"13","author":"Fabris","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-6-20241201","first-page":"294","article-title":"Failure of ketoprofen and interferon combination therapy to improve interferonresistant chronic hepatitis C.","volume":"11","author":"Anderson","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"R39-6-20241201","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.510300224","article-title":"Nonsteroidal antiinflammatory drug metabolism potentiates IFNalfa signaling by increasing STAT1 phosphorylation.","volume":"30","author":"Giambartolomei","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R40-6-20241201","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/gut.46.3.427","article-title":"Interferonalpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial.","volume":"46","author":"Munoz","year":"2000","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22215","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200805000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:14:16Z","timestamp":1733062456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200805000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22215","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}